Rivaroxaban Tablet, Film Coated
Product Images NDC 72205-416

Each tablet contains 2.5 mg of rivaroxaban USP. Store at room temperature between 20°C to 25°C. Keep out of reach of children. Pharmacist to dispense the accompanying Medication Guide to each patient. Manufactured by MSN Laboratories Private Limited in Telangana, India. Distributed by Novadoz Pharmaceuticals LLC in Piscataway, NJ.*

The text contains information about a medication called rivaroxaban in tablet form. Each tablet contains 2.5 mg of rivaroxaban USP. The recommended storage temperature is between 20°C to 25°C (68°F to 77°F), with excursions permitted to 15°C to 30°C (59°F to 86°F). It advises keeping the tablets out of reach of children and comes with a Medication Guide for patients. The tablets are manufactured by MSN Laboratories Private Limited in Telangana, India, and distributed by Novadoz Pharmaceuticals LLC in Piscataway, NJ. Full prescribing information can be found in the package insert.*

This is a description of Rivaroxaban Tablets, USP, with a strength of 25mg per tablet. The medication is intended for hospital use only and each tablet contains rivaroxaban USP. It is advised to dispense the accompanying Medication Guide to each patient. The usual storage temperature is between 20°C to 25°C, with excursions permitted between 15°C to 30°C. It is crucial to keep this medication out of reach of children. The tablets are provided in packs of 100 tablets within 10 blister strips, with 10 tablets in each strip. The manufacturer is MSN Laboratories Private Limited, and the distributor is Novadoz Pharmaceuticals LLC.*

This is a chart displaying the cumulative incidence rate (%) for Rivaroxaban and Placebo. It also includes the number of subjects at risk for each group. The data appears to be related to a medical study or clinical trial comparing the two treatments.*

This is a summary of population-specific pharmacokinetic fold changes and 90% confidence intervals for the drug rivaroxaban in various health conditions such as End-Stage Renal Disease, Renal Impairment, Age variations, Body Weight categories, and Hepatic Impairment levels. The text provides information on how the drug exposure changes in different patient populations compared to the reference group. The data includes details on postdialysis ESRD subjects, renal impairment severity, age groups, body weight categories, and hepatic impairment levels. The values reflect how factors like renal function, age, body weight, and hepatic health influence the pharmacokinetics of rivaroxaban.*

This text appears to be a list of drugs categorized by their interaction with P-gp and CYP3A enzymes, showing changes in pharmacokinetics such as fold change and 90% confidence intervals. The drugs listed include various inhibitors, inducers, and other medications like aspirin, atorvastatin, clopidogrel, digoxin, and more. The information seems to be related to drug-drug interactions and potential impact on the metabolism of these medications.*

This text provides data comparisons between Rivaroxaban and Placebo for various demographics and health conditions. It includes statistics on the effectiveness outcomes for different age groups, genders, regions, weight categories, renal function levels, medical histories, and comorbidities like diabetes and peripheral artery disease. The results show that Rivaroxaban may be more beneficial than Placebo for some subgroups based on the hazard ratios.*